Medicine Supply Notification: Quetiapine Modified-Release Tablets Shortage
A medicine supply notification has been issued for quetiapine modified-release tablets (50mg, 150mg, 200mg, 300mg, and 400mg) due to ongoing supply constraints. While immediate-release formulations remain available, prescribers and pharmacists must consider alternative options to ensure continued patient care.
Introduction:
Quetiapine is an atypical antipsychotic widely used for conditions such as schizophrenia, bipolar disorder, and major depressive disorder. The Department of Health and Social Care (DHSC) has advised that the modified-release versions of this medication are currently experiencing supply issues. This notification provides guidance on alternative treatment approaches and prescribing recommendations to support affected patients.
Key Supply Details:
The modified-release formulations of quetiapine across all strengths (50mg, 150mg, 200mg, 300mg, and 400mg) are currently in limited supply. However, quetiapine immediate-release tablets remain available and can be prescribed as an alternative, where clinically appropriate. Prescribers should carefully assess the suitability of switching to an immediate-release formulation, considering potential dosing adjustments and patient response.
For patients who require the modified-release version, unlicensed imports may be sourced through specialist suppliers. Alium Medical and Mawdsleys have confirmed their ability to procure unlicensed quetiapine modified-release tablets, though availability and lead times may vary.
Guidance for Prescribers and Pharmacists:
Where immediate-release quetiapine is deemed a suitable alternative, clinicians should provide appropriate guidance on dose adjustments and administration schedules to ensure therapeutic continuity. Patients must be monitored for potential changes in symptom control and any adverse effects following the switch.
For those requiring unlicensed modified-release quetiapine, prescriptions must be issued as an FP10 paper prescription and appropriately endorsed by the dispensing pharmacy. Pharmacists are advised to liaise with specialist importers to determine stock availability and estimated delivery times.
Implications for Clinical Practice:
This supply disruption may affect patients reliant on quetiapine modified-release tablets for symptom stability. Healthcare providers must ensure that patients receive clear guidance and ongoing support when transitioning to an alternative formulation. Regular monitoring and patient education will be essential to minimise disruption and optimise treatment outcomes.
Conclusion:
While quetiapine modified-release tablets are in short supply, the immediate-release version remains available as a clinically suitable alternative for many patients. Where required, unlicensed imports may be an option, but prescribers and pharmacists must follow the appropriate regulatory and prescribing processes. Continued communication between healthcare providers, pharmacists, and patients will be key to ensuring safe and effective medication management during this supply issue.
Citation:
Community Pharmacy England. Medicine Supply Notification: Quetiapine 50mg, 150mg, 200mg, 300mg and 400mg modified-release tablets. Published 10 February 2025. Community Pharmacy England.
Recent Resources
